Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16505395 | 1.00 | MAP3K14 (1.00) | MAP3K14PKD1 | |
| SCHEMBL30449462 | 1.00 | MAP3K14 (1.00) | MAP3K14PKD1 | |
| SCHEMBL16505565 | 0.92 | MAP3K14 (0.85) | MAP3K14PKD1 | |
| SCHEMBL16505359 | 0.91 | MAP3K14 (0.84) | MAP3K14PKD1 | |
| SCHEMBL16505429 | 0.91 | MAP3K14 (0.83) | MAP3K14PKD1 | |
| SCHEMBL16505635 | 0.90 | MAP3K14 (0.81) | MAP3K14PKD1 | |
| SCHEMBL16505559 | 0.89 | MAP3K14 (0.84) | MAP3K14PKD1 | |
| SCHEMBL16505759 | 0.88 | MAP3K14 (0.82) | MAP3K14PKD1 | |
| SCHEMBL16505474 | 0.88 | MAP3K14 (0.82) | MAP3K14PKD1 | |
| SCHEMBL16505482 | 0.88 | MAP3K14 (1.00) | MAP3K14PKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118001409-A | Kit for the treatment and/or co-treatment of T cell mediated immune disorders | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2024-05-10 | — | — | CN | claimed |
| WO-2023101457-A1 | COMPOSITION FOR PREVENTING OR TREATING BILIARY TRACT CANCER | 연세대학교 산학협력단 | 2023-06-08 | — | — | WO | claimed |
| US-20210355221-A1 | Targeting the Non-Canonical NFkB Pathway in Cancer Immunotherapy | THE GENERAL HOSPITAL CORPORATION | 2021-11-18 | — | — | US | claimed |
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2025-10-02 | — | — | US | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12364681-B2 | Combined MAPK and NAMPT inhibition for treatment of neuron degeneration | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-07-22 | — | — | US | disclosed |
| EP-4540249-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | Yeda Research and Development Co. Ltd (IL) | 2025-04-23 | — | — | EP | disclosed |
| US-20250026722-A1 | SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS | Université Côte d’Azur (FR) | 2025-01-23 | — | — | US | disclosed |
| US-20240415801-A1 | Methods and Compositions for Treating Fibroids | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 2024-12-19 | — | — | US | disclosed |
| US-20240285599-A1 | Mature-Hepatocyte Transdifferentiation Suppressing Composition | OSAKA UNIVERSITY (JP) | 2024-08-29 | — | — | US | disclosed |
| EP-4399202-A1 | SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS | Yukin Therapeutics (FR) | 2024-07-17 | — | — | EP | disclosed |
| US-20170210724-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20160185797-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160185797-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| EP-3036229-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015025026-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-26 | — | — | WO | disclosed |
| WO-2015025026-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-26 | — | — | WO | disclosed |
| US-20150057260-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150057260-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150057260-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285599-A1 | Mature-Hepatocyte Transdifferentiation Suppressing Composition | TRAF2, IKBKG, TRAF6 | MAP3K14 44/4885PKD1 1675/4885 |
| US-20250026722-A1 | SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS | NFKBIA, IKBKG, IKBKB | MAP3K14 34/4885PKD1 1395/4885 |
| US-20150057260-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, NFKBIA | MAP3K14 553/4885PKD1 2437/4885 |
| US-20170210724-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, NFKBIA | MAP3K14 553/4885PKD1 2437/4885 |
| US-20160185797-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, NFKBIA | MAP3K14 553/4885PKD1 2437/4885 |
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | CASR, NPSR1, GSR | MAP3K14 3635/4885PKD1 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.